Eli Lilly and Company $LLY Shares Acquired by Synergy Asset Management LLC

Synergy Asset Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 554.1% during the second quarter, Holdings Channel.com reports. The fund owned 26,865 shares of the company’s stock after purchasing an additional 22,758 shares during the period. Eli Lilly and Company accounts for about 2.4% of Synergy Asset Management LLC’s holdings, making the stock its 13th biggest holding. Synergy Asset Management LLC’s holdings in Eli Lilly and Company were worth $20,942,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in LLY. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC acquired a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. grew its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Cohen Investment Advisors LLC grew its position in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock worth $647,225,000 after buying an additional 773,947 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after buying an additional 765,010 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on LLY. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $939.61.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jamere Jackson bought 200 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Trading Down 0.6%

NYSE LLY opened at $820.69 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $776.75 billion, a price-to-earnings ratio of 53.64, a PEG ratio of 1.15 and a beta of 0.47. The firm’s 50 day moving average price is $734.03 and its two-hundred day moving average price is $766.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the company posted $3.92 EPS. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.